BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Enguita-Germán M, Fortes P. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol 2014; 6(10): 716-737 [PMID: 25349643 DOI: 10.4254/wjh.v6.i10.716] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Tao Y, Wang M, Chen E, Tang H. Liver Regeneration: Analysis of the Main Relevant Signaling Molecules. Mediators Inflamm 2017;2017:4256352. [PMID: 28947857 DOI: 10.1155/2017/4256352] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 11.4] [Reference Citation Analysis]
2 Nascimbeni F, Aron-Wisnewsky J, Pais R, Tordjman J, Poitou C, Charlotte F, Bedossa P, Poynard T, Clément K, Ratziu V. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016;3:e000075. [PMID: 27110380 DOI: 10.1136/bmjgast-2015-000075] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
3 Chi X, Jiang L, Yuan Y, Huang X, Yang X, Hochwald S, Liu J, Huang H. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02279-w] [Reference Citation Analysis]
4 Chen L, Wei Y, Zhao S, Zhang M, Yan X, Gao X, Li J, Gao Y, Zhang A, Gao Y. Antitumor and immunomodulatory activities of total flavonoids extract from persimmon leaves in H22 liver tumor-bearing mice. Sci Rep 2018;8:10523. [PMID: 30002398 DOI: 10.1038/s41598-018-28440-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
5 da Silva MR, Moreira GA, Gonçalves da Silva RA, de Almeida Alves Barbosa É, Pais Siqueira R, Teixera RR, Almeida MR, Silva Júnior A, Fietto JL, Bressan GC. Splicing Regulators and Their Roles in Cancer Biology and Therapy. Biomed Res Int 2015;2015:150514. [PMID: 26273588 DOI: 10.1155/2015/150514] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
6 Liu H, Xu H, Zhang C, Gao M, Gao X, Ma C, Lv L, Gao D, Deng S, Wang C, Tian Y. Emodin-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles to Enhance Chemotherapeutic Efficacy Against Liver Cancer. Pharm Res 2016;33:2828-43. [PMID: 27511028 DOI: 10.1007/s11095-016-2010-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Alves A, Mamede A, Alves M, Oliveira P, Rocha S, Botelho M, Maia C. Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment? CCDT 2018;19:26-40. [DOI: 10.2174/1568009618666180430144441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
8 Moustafa EM, Rashed LA, El-sebaie MM, Thabet NM, Abdel-rafei MK. Crosstalk between ER-stress and apoptosis in irradiated HepG2 cells with gemcitabine: implication of PI3K/AKT and IκB/NF-κB signaling pathways. Journal of Radiation Research and Applied Sciences 2020;13:144-54. [DOI: 10.1080/16878507.2020.1715569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Yoshida GJ, Azuma A, Miura Y, Orimo A. Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies. Int J Mol Sci 2019;20:E2256. [PMID: 31067787 DOI: 10.3390/ijms20092256] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 18.0] [Reference Citation Analysis]
11 Al Hrout A, Cervantes-Gracia K, Chahwan R, Amin A. Modelling liver cancer microenvironment using a novel 3D culture system. Sci Rep 2022;12:8003. [PMID: 35568708 DOI: 10.1038/s41598-022-11641-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Brito AF, Abrantes AM, Tralhão JG, Botelho MF. Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev 2016;10:302. [PMID: 27994769 DOI: 10.4081/oncol.2016.302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
13 Agosti P, Sabbà C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:607-17. [DOI: 10.1016/j.bbadis.2017.11.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
14 Cervello M, Augello G, Cusimano A, Emma MR, Balasus D, Azzolina A, Mccubrey JA, Montalto G. Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma. Advances in Biological Regulation 2017;65:59-76. [DOI: 10.1016/j.jbior.2017.06.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
15 Cheng J, Zhong Y, Chen S, Sun Y, Huang L, Kang Y, Chen B, Chen G, Wang F, Tian Y, Liu W, Feng GS, Lu Z. Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways. FASEB J 2017;31:5530-42. [PMID: 28842424 DOI: 10.1096/fj.201700120RR] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
16 Sivasudhan E, Blake N, Lu ZL, Meng J, Rong R. Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:642443. [PMID: 33869193 DOI: 10.3389/fcell.2021.642443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Zhao C, Wang Q, Wang B, Sun Q, He Z, Hong J, Kuehn F, Liu E, Zhang Z. IGF-1 induces the epithelial-mesenchymal transition via Stat5 in hepatocellular carcinoma. Oncotarget 2017;8:111922-30. [PMID: 29340101 DOI: 10.18632/oncotarget.22952] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
18 Wang X, Lin L, Lan B, Wang Y, Du L, Chen X, Li Q, Liu K, Hu M, Xue Y, Roberts AI, Shao C, Melino G, Shi Y, Wang Y. IGF2R-initiated proton rechanneling dictates an anti-inflammatory property in macrophages. Sci Adv 2020;6:eabb7389. [PMID: 33239287 DOI: 10.1126/sciadv.abb7389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Shimizu M, Shirakami Y, Sakai H, Kubota M, Kochi T, Ideta T, Miyazaki T, Moriwaki H. Chemopreventive potential of green tea catechins in hepatocellular carcinoma. Int J Mol Sci 2015;16:6124-39. [PMID: 25789501 DOI: 10.3390/ijms16036124] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
20 Lee SM, Kim-Ha J, Choi WY, Lee J, Kim D, Lee J, Choi E, Kim YJ. Interplay of genetic and epigenetic alterations in hepatocellular carcinoma. Epigenomics 2016;8:993-1005. [PMID: 27411963 DOI: 10.2217/epi-2016-0027] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
21 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
22 Glück AA, Aebersold DM, Zimmer Y, Medová M. Interplay between receptor tyrosine kinases and hypoxia signaling in cancer. The International Journal of Biochemistry & Cell Biology 2015;62:101-14. [DOI: 10.1016/j.biocel.2015.02.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
23 Lippolis C, Refolo MG, D'Alessandro R, Carella N, Messa C, Cavallini A, Carr BI. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1. J Exp Clin Cancer Res 2015;34:90. [PMID: 26329608 DOI: 10.1186/s13046-015-0210-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
24 Nault J. Reports from the International Liver Cancer Association (ILCA) congress 2014. Journal of Hepatology 2015;62:477-82. [DOI: 10.1016/j.jhep.2014.11.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
25 Sobrevals L, Enguita M, Quiroga J, Prieto J, Fortes P. Insulin-Like Growth Factor I (IGF-I) Expressed from an AAV1 Vector Leads to a Complete Reversion of Liver Cirrhosis in Rats. PLoS One 2016;11:e0162955. [PMID: 27658043 DOI: 10.1371/journal.pone.0162955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
26 Al-Tamimi J, Semlali A, Hassan I, Ebaid H, Alhazza IM, Mehdi SH, Al-Khalifa M, Alanazi MS. Samsum Ant Venom Exerts Anticancer Activity Through Immunomodulation In Vitro and In Vivo. Cancer Biother Radiopharm 2018;33:65-73. [PMID: 29634416 DOI: 10.1089/cbr.2017.2400] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
27 Wang F, Bank T, Malnassy G, Arteaga M, Shang N, Dalheim A, Ding X, Cotler SJ, Denning MF, Nishimura MI, Breslin P, Qiu W. Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. Hepatol Commun 2018;2:732-46. [PMID: 29881824 DOI: 10.1002/hep4.1181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
28 Chen J, Liang J, Liu S, Song S, Guo W, Shen F. Differential regulation of AKT1 contributes to survival and proliferation in hepatocellular carcinoma cells by mediating Notch1 expression. Oncol Lett 2018;15:6857-64. [PMID: 29725418 DOI: 10.3892/ol.2018.8193] [Reference Citation Analysis]
29 Redman JM, Hill EM, AlDeghaither D, Weiner LM. Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol 2015;67:28-45. [PMID: 25911943 DOI: 10.1016/j.molimm.2015.04.002] [Cited by in Crossref: 85] [Cited by in F6Publishing: 72] [Article Influence: 12.1] [Reference Citation Analysis]
30 Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 2015;21:4103-10. [PMID: 25892859 DOI: 10.3748/wjg.v21.i14.4103] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 88] [Article Influence: 13.9] [Reference Citation Analysis]
31 Ceylan H. Identification of hub genes associated with obesity-induced hepatocellular carcinoma risk based on integrated bioinformatics analysis. Med Oncol 2021;38:63. [PMID: 33900477 DOI: 10.1007/s12032-021-01510-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Yousaf T, Sun Y, Naz W, Liu Y, Xu J, Yuan S, Wu K, Wang M, Wang J, Guo M, Sun G. Multiomics Analysis of Endocytosis upon HBV Infection and Identification of SCAMP1 as a Novel Host Restriction Factor against HBV Replication. IJMS 2022;23:2211. [DOI: 10.3390/ijms23042211] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Chen M, Zhou X, Chen R, Wang J, Ye RD, Wang Y, Wu C, Mahato RI. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today 2019;25:66-87. [DOI: 10.1016/j.mattod.2018.10.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
34 Moon H, Ro SW. MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3026. [PMID: 34204242 DOI: 10.3390/cancers13123026] [Reference Citation Analysis]
35 Khan MGM, Ghosh A, Variya B, Santharam MA, Ihsan AU, Ramanathan S, Ilangumaran S. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma. BMC Cancer 2020;20:774. [PMID: 32807134 DOI: 10.1186/s12885-020-07285-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
36 Li H, Jiang X, Zhu S, Sui L. Identification of personalized dysregulated pathways in hepatocellular carcinoma. Pathol Res Pract 2017;213:327-32. [PMID: 28215647 DOI: 10.1016/j.prp.2017.01.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
37 Fleming BD, Ho M. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins (Basel) 2016;8:E274. [PMID: 27669301 DOI: 10.3390/toxins8100274] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
38 Mobasher MA, Germoush MO, Galal El-Tantawi H, Samy El-Said K. Metformin Improves Biochemical and Pathophysiological Changes in Hepatocellular Carcinoma with Pre-Existed Diabetes Mellitus Rats. Pathogens 2021;10:59. [PMID: 33440701 DOI: 10.3390/pathogens10010059] [Reference Citation Analysis]
39 Chen C, Wang G. Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol 2015; 7(15): 1964-1970 [PMID: 26244070 DOI: 10.4254/wjh.v7.i15.1964] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 10.7] [Reference Citation Analysis]
40 Subbotin VM. A hypothesis on paradoxical privileged portal vein metastasis of hepatocellular carcinoma. Can organ evolution shed light on patterns of human pathology, and vice versa? Med Hypotheses 2019;126:109-28. [PMID: 31010487 DOI: 10.1016/j.mehy.2019.03.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Lou Z, Gong YQ, Zhou X, Hu GH. Low expression of miR-199 in hepatocellular carcinoma contributes to tumor cell hyper-proliferation by negatively suppressing XBP1. Oncol Lett 2018;16:6531-9. [PMID: 30405792 DOI: 10.3892/ol.2018.9476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
42 Barbhuiya MA, Mirando AC, Simons BW, Lemtiri-Chlieh G, Green JJ, Popel AS, Pandey NB, Tran PT. Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma. Oncotarget 2017;8:101520-34. [PMID: 29254183 DOI: 10.18632/oncotarget.21148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
43 El-Din MS, Taha AM, Sayed AA, Salem AM. Ziziphus spina-christi leaves methanolic extract alleviates diethylnitrosamine-induced hepatocellular carcinoma in rats. Biochem Cell Biol 2019;97:437-45. [PMID: 30605366 DOI: 10.1139/bcb-2018-0318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Subbotin VM. Privileged portal metastasis of hepatocellular carcinoma in light of the coevolution of a visceral portal system and liver in the chordate lineage: a search for therapeutic targets. Drug Discov Today 2018;23:548-64. [PMID: 29330122 DOI: 10.1016/j.drudis.2018.01.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
45 Fujita K, Iwama H, Miyoshi H, Tani J, Oura K, Tadokoro T, Sakamoto T, Nomura T, Morishita A, Yoneyama H, Masaki T. Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol 2016; 22(27): 6100-6113 [PMID: 27468203 DOI: 10.3748/wjg.v22.i27.6100] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]